Dr. Lal Path Labs Intrinsic Value
LALPATHLAB • Healthcare Services
Current Stock Price
₹1312.10
Primary Intrinsic Value
₹866.40
Market Cap
₹110.2K Cr
-54.7%
Downside
Median Value
₹594.93
Value Range
₹263 - ₹1158
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
LALPATHLAB Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹866.40 | ₹693.12 - ₹1039.68 | -34.0% | EPS: ₹72.20, Sector P/E: 12x |
| Book Value Method | asset | ₹262.74 | ₹236.47 - ₹289.01 | -80.0% | Book Value/Share: ₹262.74, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹393.63 | ₹354.27 - ₹432.99 | -70.0% | Revenue/Share: ₹359.52, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹711.43 | ₹640.29 - ₹782.57 | -45.8% | EBITDA: ₹996.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹743.79 | ₹595.03 - ₹892.55 | -43.3% | CF Growth: 9.3%, Discount: 15% |
| PEG Ratio Method | growth | ₹462.08 | ₹415.87 - ₹508.29 | -64.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹594.93 | ₹535.44 - ₹654.42 | -54.7% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1158.10 | ₹1042.29 - ₹1273.91 | -11.7% | ROE: 27.5%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹525.48 | ₹472.93 - ₹578.03 | -60.0% | EPS: ₹72.20, BVPS: ₹262.74 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
LALPATHLAB Intrinsic Value Analysis
What is the intrinsic value of LALPATHLAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Dr. Lal Path Labs (LALPATHLAB) is ₹594.93 (median value). With the current market price of ₹1312.10, this represents a -54.7% variance from our estimated fair value.
The valuation range spans from ₹262.74 to ₹1158.10, indicating ₹262.74 - ₹1158.10.
Is LALPATHLAB undervalued or overvalued?
Based on our multi-method analysis, Dr. Lal Path Labs (LALPATHLAB) appears to be trading above calculated value by approximately 54.7%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.63 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 27.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.11x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Dr. Lal Path Labs
Additional stock information and data for LALPATHLAB
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹569 Cr | ₹418 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹535 Cr | ₹523 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹456 Cr | ₹313 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹447 Cr | ₹223 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹398 Cr | ₹292 Cr | Positive Free Cash Flow | 8/10 |